Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorApplied Biology, Inc.
About this trial
The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).
Eligibility criteria
Qualifiers
Age 18 or older
Diagnosed with androgenetic alopecia
Willing and able to apply the treatment as directed, comply with study
Otherwise healthy
Disqualifiers
A medical history that may interfere with study objectives
Women who are pregnant, lactating, or planning to become pregnant during the study period
Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)
Subjects who have known allergies to any excipient in DA-002 or DA-005
Trial design
Treatments tested in this trial
- DA-005
- Topical minoxidil 5%
- DA-002
- Placebo Oral Tablet
- Placebo Topical Solution
Treatment groups
516 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Applied Biology, Inc.
Lead sponsor
Follea International Limited
Collaborator
Daniel Alain, Inc.
Collaborator
Source ClinicalTrials.gov